Original ArticleDetermination of lercanidipine in human plasma by an improved UPLC–MS/MS method for a bioequivalence study☆

Add time:08/31/2019    Source:sciencedirect.com

An improved and reliable ultra-performance liquid chromatography/tandem mass spectrometry (UPLC–MS/MS) method has been developed and validated for the determination of lercanidipine in human plasma. Plasma samples with lercanidipine-d3 as an internal standard (IS) were prepared by solid phase extraction on Phenomenex Strata-X cartridges using 100 µL of human plasma. Chromatographic analysis was performed on UPLC BEH C18 (50 mm×2.1 mm, 1.7 µm) column under isocratic conditions. Linear calibration curves were obtained over a wide dynamic concentration range of 0.010–20.0 ng/mL. Matrix effect was assessed by post-column infusion, post-extraction spiking and standard-line slope methods. The mean extraction recovery was >94% for the analyte and IS. Inter-batch and intra-batch precision (% CV) across five quality controls was <5.8%. Bioequivalence study was performed with 36 healthy subjects after oral administration of 10 mg of lercanidipine and the assay reproducibility was evaluated by reanalysis of 133 incurred samples.

We also recommend Trading Suppliers and Manufacturers of Lercanidipine hydrochloride (cas 132866-11-6). Pls Click Website Link as below: cas 132866-11-6 suppliers

Prev:Invited paperSubstituent effect of side chains on the photochemical behavior of a new generation 1,4-dihydropyridine: Lercanidipine
Next:Research paperDevelopment of fast dissolving oral films containing lercanidipine HCl nanoparticles in semicrystalline polymeric matrix for enhanced dissolution and ex vivo permeation)